Komatsu H, Furuse K, Nishikawa H, Minoda S, Saotome K, Nemoto E, Tani Y, Saito T, Ishiwata K, Tsutsumi M
Dept. of Surgery for Chest Disease, National Tokyo Hospital.
Gan To Kagaku Ryoho. 1988 Aug;15(8):2313-8.
A phase II clinical trial of carboplatin for small cell lung cancer was conducted in 20 institutions of the National Chest Hospital lung cancer cooperative study group. Carboplatin was administered by three dosing schedule of 300 mg/m2, 400 mg/m2 and 450 mg/m2. Out of 30 patients registered in this trial, 29 patients were evaluable for response and toxicity. Seven patients achieved PR with the response rate of 24.1%. The response rates for 300 mg/m2, for 400 mg/m2 and for 450 mg/m2 were 25.0%, 8.3% and 44.4%, respectively. Thrombocytopenia (less than 7 x 10(4)/mm3) and leukopenia (less than 3,000/mm3) were observed at 25.9% and 17.2% of cases, respectively. Nausea/vomiting was also observed at an incidence of 55.2% with mild degree. No renal and ototoxic damage was observed.
国家胸科医院肺癌合作研究组的20个机构开展了一项卡铂用于小细胞肺癌的II期临床试验。卡铂采用300mg/m²、400mg/m²和450mg/m²三种给药方案。在该试验登记的30例患者中，29例可评估疗效和毒性。7例患者达到部分缓解，缓解率为24.1%。300mg/m²、400mg/m²和450mg/m²的缓解率分别为25.0%、8.3%和44.4%。血小板减少（低于7×10⁴/mm³）和白细胞减少（低于3000/mm³）分别在25.9%和17.2%的病例中观察到。恶心/呕吐的发生率也为55.2%，程度较轻。未观察到肾毒性和耳毒性损害。
